"copper dotatate CU-64"[nm] - Search Results

Year	Number of Results
2020	6
2021	55
2022	184
2023	95
2024	27

1

Ichikawa Y, Kobayashi N, Takano S, Kato I, Endo K, Inoue T. Ichikawa Y, et al. Cancer Sci. 2022 Jun;113(6):1930-1938. doi: 10.1111/cas.15327. Epub 2022 Apr 11. Cancer Sci. 2022. PMID: 35271754 Free PMC article. Review.

2

⁶⁴Cu-DOTATATE, the growing signal for PET imaging of vascular inflammation?

Deshayes S, Manrique A. Deshayes S, et al. J Nucl Cardiol. 2023 Jun;30(3):1001-1003. doi: 10.1007/s12350-022-03110-5. Epub 2022 Sep 30. J Nucl Cardiol. 2023. PMID: 36180768 No abstract available.

3

[⁶⁴Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans.

Jensen JK, Madsen JS, Jensen MEK, Kjaer A, Ripa RS. Jensen JK, et al. J Nucl Cardiol. 2023 Jun;30(3):986-1000. doi: 10.1007/s12350-022-03084-4. Epub 2022 Aug 31. J Nucl Cardiol. 2023. PMID: 36045250 Free PMC article.

4

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.

Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. Fortunati E, et al. Curr Treat Options Oncol. 2022 May;23(5):703-720. doi: 10.1007/s11864-022-00967-z. Epub 2022 Mar 24. Curr Treat Options Oncol. 2022. PMID: 35325412 Free PMC article. Review.

5

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

Harris PE, Zhernosekov K. Harris PE, et al. Front Endocrinol (Lausanne). 2022 Oct 31;13:941832. doi: 10.3389/fendo.2022.941832. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387893 Free PMC article. Review.

6

Activity Dose Reduction in ⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability.

Loft M, Carlsen EA, Johnbeck CB, Jensen CV, Andersen FL, Langer SW, Oturai P, Knigge U, Kjaer A. Loft M, et al. Mol Imaging Biol. 2022 Aug;24(4):600-611. doi: 10.1007/s11307-022-01706-4. Epub 2022 Feb 15. Mol Imaging Biol. 2022. PMID: 35167028

7

Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.

Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R. Delpassand ES, et al. J Nucl Med. 2022 Sep;63(9):1326-1333. doi: 10.2967/jnumed.121.263230. Epub 2022 Jan 6. J Nucl Med. 2022. PMID: 34992153 Free PMC article.

8

Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

Kandathil A, Subramaniam RM. Kandathil A, et al. PET Clin. 2023 Apr;18(2):189-200. doi: 10.1016/j.cpet.2022.11.001. Epub 2022 Dec 28. PET Clin. 2023. PMID: 36585339 Review.

9

Radiopharmaceuticals for Neuroendocrine Tumors.

Chin RI, Wu FS, Menda Y, Kim H. Chin RI, et al. Semin Radiat Oncol. 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. Semin Radiat Oncol. 2021. PMID: 33246637 Review.

10

Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume.

Carlsen EA, Johnbeck CB, Loft M, Pfeifer A, Oturai P, Langer SW, Knigge U, Ladefoged CN, Kjaer A. Carlsen EA, et al. J Nucl Med. 2021 Nov;62(11):1564-1570. doi: 10.2967/jnumed.120.258392. Epub 2021 Feb 26. J Nucl Med. 2021. PMID: 33637589 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

297 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year